Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (3y) (2021 - 2026)
Takeda Pharmaceutical (TAK) FCF Payout Ratio Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 34.17% |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.45 Bn | 4.39 Bn | -43.00% |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn | 37.03% |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.00% |
| Dec 31, 2025 | -4.66% |
| Sep 30, 2025 | 22.13% |
| Jun 30, 2025 | 18.52% |
| Mar 31, 2025 | -49.60% |
| Dec 31, 2024 | 1.13% |
| Sep 30, 2024 | 8.34% |
| Jun 30, 2024 | 3.33% |
| Mar 31, 2024 | -114.35% |
| Dec 31, 2023 | -9.23% |
| Sep 30, 2023 | -6.62% |
| Jun 30, 2023 | -6.26% |
| Mar 31, 2023 | 51.09% |
| Sep 30, 2022 | -41.14% |
| Jun 30, 2022 | -4.99% |
| Mar 31, 2022 | 27.82% |
| Dec 31, 2021 | 16.62% |
| Sep 30, 2021 | 19.05% |
| Jun 30, 2021 | 14.70% |
| Mar 31, 2021 | -27.84% |